comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 00:37:53 - browse：2

UnitedHealth Group’s Optum subsidiary saw a lower operating margin in the second quarter due to more seniors getting care, a spike in demand for behavioral health services, and an influx of members with higher health needs.

“Those three elements, the senior trend piece, the behavioral piece, and then the effects of the strong growth is really what explains what’s going on,” UnitedHealth Group CEO Andrew Witty said on the company’s earnings call on Friday. “We’ll continue to lean into that growth very assertively.”

Minnetonka, Minn.-based UnitedHealth Group’s Optum segment, which includes its provider arm, its pharmacy benefit manager, and its data and technology arm, reported an operating margin of 6.6% in the quarter ended June 30, compared with 7.3% in the prior-year period. Leaders said the decline was within its provider arm, Optum Health.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Steward Health Care Massachusetts hospitals face fiscal disaster

WSS

Change Healthcare outage fallout shows need for new oversight

Male and female sex labels in research insufficient, scientists say

What happened to the House vote on health price transparency?

Midwives could help bridge maternal health disparities in the U.S.

People with substance use disorder deserve online privacy

RaDonda Vaught links Vanderbilt hospital issues to patient death

explore

comprehensive

entertainment

Affirmative action in medical school literally saved lives

How to save health care price transparency rules

Drug repurposing or repositioning? The language matters

PBMs drew scrutiny in House hearing — and so did pharma

Medicare details structure of new drug price negotiation program

FDA panel to weigh safety of artificial wombs for preterm births

United colonoscopy coverage change 'may cost lives,' doctors say

First U.S. drug developed to treat liver disease MASH is approved

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA panel to weigh safety of artificial wombs for preterm births

Wikipedia

Why the quest to eradicate polio has stumbled

UCLA team creates talking throat patch for voice disorders

FDA advisers back CAR

Pushing for an NIH office for post

First U.S. drug developed to treat liver disease MASH is approved

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

knowledge

leisure time

knowledge

focus